Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-Label Study of iratumumab (MDX-060) in Relapsed or Refractory Hodgkin's Disease
2004-004604-20Phase 2Completed
- Sponsor
- Medarex, Inc.
- Start
- Feb 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of iratumumab in Hodgkin lymphoma (HL), sponsored by Medarex, Inc.. Started Feb 2005; status: completed.
02
Drugs
iratumumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2004-004604-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004604-20.